In the latest episode of Exchanges at Goldman Sachs, **Salveen Richter, Lead Analyst for the U.S. Biotechnology Sector in Goldman Sachs Research, **explains how new innovations in gene editing are transforming the future of medicine and the greater biotech investment landscape.
